NEW HAVEN, Conn., April 2, 2008 (PRIME NEWSWIRE) -- Achillion Pharmaceuticals, Inc., (Nasdaq:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the appointment of Gary E. Frashier to its Board of Directors. Mr. Frashier, a principal with Management Associates, a consultant to entrepreneurial companies, brings extensive experience in life science company transactions and commercial operations. He will serve on Achillion's compensation and nominating/governance committees.
